Cerebrospinal fluid (CSF) biomarkers, including T-tau, P-tau, and Aβ1–42, have also been widely studied and incorporated into current diagnostic criteria of AD [10, 16]. The gene discussed is MAPT; the disease is Alzheimer disease.